Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010

ABSTRACT

The conventional management of thrombotic and cardiovascular disorders is based on the use of heparin, oral anticoagulants, and aspirin. Despite remarkable progress in life sciences, these drugs still remain a challenge and a mystery to us, and their use is far from optimized. The development of low-molecular-weight heparins and the synthesis of heparinomimetics, such as the chemically synthesized pentasaccharide, represent a refined use of heparin. Additional drugs from this knowledge will continue to develop; however, none of these drugs will ever match the polypharmacology of heparin. Aspirin still remains the leading drug in the management of thrombotic and cardiovascular disorders. The newer antiplatelet drugs such as adenosine diphosphate receptor inhibitors, glycoprotein IIb/IIIa inhibitors, and other specific inhibitors have limited effects and have been tested in patients who have already been treated with aspirin. Warfarin provides a convenient and affordable approach in the long-term outpatient management of thrombotic disorders. The optimized use of these drugs still remains as the approach of choice to manage thrombotic disorders. The new anticoagulant targets, including specific sites in the hemostatic network such as tissue factor, individual clotting factors (IIa, VIIa, IXa, Xa, XIIa, and XIIIa), recombinant forms of serpins (antithrombin, heparin cofactor II, and tissue factor pathway inhibitors), recombinant activated protein C, thrombomodulin, and site-specific serine protease inhibitor complexes have also been developed. There is a major thrust on the development of orally bioavailable anticoagulant drugs (anti-Xa and anti-IIa agents), which are slated to replace oral anticoagulants. Both the anti-factor Xa and antithrombin agents have been developed for oral use and have provided impressive clinical outcomes in sponsor trials for the postsurgical prophylaxis of venous thrombosis; however, safety concerns related to liver enzyme elevations and thrombosis rebound have been reported with their use. For these reasons, the U.S. Food and Drug Administration did not approve the orally active antithrombin agent ximelagatran for several indications. The synthetic pentasaccharide (fondaparinux) has undergone an aggressive clinical development. Unexpectedly, fondaparinux also produced major bleeding problems at minimal dosages. Fondaparinux represents only one of the multiple pharmacologic effects of heparins. Thus, its therapeutic index will be proportionately narrower. The newer antiplatelet drugs have added a new dimension in the management of thrombotic disorders. The favorable clinical outcomes with aspirin and clopidogrel have validated cyclooxygenase (COX)-1 and P2Y₁₂ receptors as targets for new drug development. Prasugrel, a novel thienopyridine, cangrelor, and AZD 6140 represent newer P2Y₁₂ antagonists. Cangrelor and AZD 6140 are direct inhibitors, whereas prasugrel requires metabolic activation. Though clinically effective, recent results have prompted a closure of a large clinical trial with prasugrel due to bleeding. The newer anticoagulant and antiplatelet drugs are attractive for several reasons; however, none of these are expected to replace the conventional drugs in polytherapeutic approaches. Heparins, warfarin, and aspirin will continue to play a major role in the management of thrombotic and cardiovascular disorders beyond 2010.

KEYWORDS

Heparin - warfarin - aspirin - antithrombins - anti-Xa agents

REFERENCES

• 1 Fareed J, Hoppensteadt D A, Bick R L. Management of thrombotic and cardiovascular disorders in the new millennium.  Clin Appl Thromb Hemost. 2003;  9 101-108
• 2 Fareed J, Hoppensteadt D A. The management of thrombotic and cardiovascular disorders in the 21st century. In: Sasahara AA, Loscalzo J New Therapeutic Agents in Thrombosis and Thrombolysis. 2nd ed. New York, NY; Marcel Dekker 2002: 687-693
• 3 Eikelboom J W, Weitz J I. A replacement for warfarin: the search continues.  Circulation. 2007;  116 131-133
• 4 Bates S M, Weitz J I. The status of new anticoagulants.  Br J Haematol. 2006;  134 3-19
• 5 Laux V, Hinder M. Rationale for direct factor Xa inhibitors in acute coronary syndromes. In: Kipshidze N, Fareed J, Moses JW, Serruys PW Textbook of International Cardiovascular Pharmacology. Andover, UK; Informa Healthcare 2007: 119-126
• 6 Leong W, Hoppensteadt D A. Generic forms of low molecular weight heparins: some practical considerations.  Clin Appl Thromb Hemost. 2003;  9 293-297
• 7 Marmur J D, Anand S X, Bagga R S et al.. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.  J Am Coll Cardiol. 2003;  41 394-402
• 8 Fox K A. Implications of the organization to assess strategies for ischemic syndromes-2 (OASIS-2) study and the results in the context of other trials.  Am J Cardiol. 1999;  84 26M-31M
• 9 Lee A Y, Levine M N, Baker R I et al.. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med. 2003;  349 146-153
• 10 Linkins L A, Weitz J I. Pharmacology and clinical potential of direct thrombin inhibitors.  Curr Pharm Des. 2005;  11 3877-3884
• 11 Antman E M. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibitors in myocardial infarction (TIMI) 9B trial.  Circulation. 1996;  94 911-921
• 12 Cho L, Bhatt D L, Marso S P et al.. An invasive strategy is associated with decreased mortality in patients with acute coronary syndrome and non-ST elevation myocardial infarction: GUSTO IIb trial.  Am J Med. 2003;  114 106-111
• 13 Eriksson B I, Ekman S, Lindbratt S et al.. Prevention of thromboembolism with use of recombinant hirudin: results of a double blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am. 1997;  79 326-333
• 14 Eriksson B I, Wille-Jorgensen P, Kalebo P et al.. a comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335
• 15 Lincoff A M, Bittl J A, Harrington R A et al. for the REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial.  JAMA. 2003;  289 853-863
• 16 Stone G W, McLaurin B T, Cox D A et al. for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes.  N Engl J Med. 2006;  355 2203-2216
• 17 Stone G W, Bertrand M E, Moses J W et al.. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.  JAMA. 2007;  297 591-602
• 18 Stone G W, White H D, Ohman E M et al.. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.  Lancet. 2007;  369 907-919
• 19 Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against lepirudin are polyspecifc and recognize epitopes on bivalirudin.  Blood. 2004;  103 613-616
• 20 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
• 21 Lewis B E, Wallis D E, Leya F et al.. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
• 22 Dahl O E, Eriksson B I, Agnelli G et al.. Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopedic surgery: effects of timing of finishing factors for thromboembolism and bleeding complications on efficacy and safety.  Clin Drug Investig. 2005;  25 65-77
• 23 Kalus J S, Caron M F. Novel uses for current and future direct thrombin inhibitors; focus on ximelagatran and bivalirudin.  Expert Opin Investig Drugs. 2004;  13 465-477
• 24 Turpie A G, Fisher W D, Bauer K A et al.. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.  J Thromb Haemost. 2005;  3 2479-2486
• 25 Erikkson B I, Borris L, Dahl O et al.. Oral, direct factor Xa inhibition with Bay 59-7939 for the prevention of venous thromboembolism after total hip replacement.  J Thromb Haemost. 2006;  4 121-128
• 26 Yusuf S, Mehta S R, Chrolavicius S et al.. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.  JAMA. 2006;  295 1519-1530
• 27 Saiah E, Soares C. Small molecule coagulation inhibitors in the clinic.  Curr Trends Med Chem. 2005;  5 1677-1695
• 28 Aherns I, Smith B K, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.  Expert Opin Drug Metab Toxicol. 2007;  3 609-620
• 29 Lewis B E, Matthai Jr W H, Cohen M et al.. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced- thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
• 30 Alexander J H, Yang H, Becker R C et al.. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the Xa NADV-ACS trial.  J Thromb Haemost. 2005;  3 439-447
• 31 Cohen M, Bhatt D L, Alexander J H et al.. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.  Circulation. 2007;  115 2642-2651
• 32 CAPRIE Steering Committee . A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
• 33 Smith S C, Feldman T E, Hirschfeld J W, Jacobs A K. American College of Cardiology/American Heart Association Task Force on practice guidelines. ACC/AHA/SCA 2005.  Circulation. 2006;  113 e166-e186
• 34 Bhatt D L, Bertrand M E, Berger P B. Meta-analysis of randomized and registry comparison of ticlopidine with clopidogrel after stenting.  J Am Coll Cardiol. 2002;  39 9-14
• 35 Bauer K A, Eriksson B I, Lassen M R, Turpie A G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1313
• 36 Hirsh J, Guyatt G H, Albers G W, Schunemann H J. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines.  Chest. 2004;  126 163S-703S
• 37 Fareed J. Anticoagulant management of patients undergoing interventional procedures. In: Kipshidze N, Fareed J, Moses JW, Serruys PW Textbook of International Cardiovascular Pharmacology. Andover, UK; Informa Healthcare 2007: 613-619
• 38 Flaker G C, Gruber M, Connolly S J et al.. SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.  Am Heart J. 2006;  152 967-973
• 39 Peterson P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: a dose guiding tolerability and safety study.  J Am Coll Cardiol. 2003;  41 1445-1451